PF-07220060 + enzalutamide

PF-07220060 + enzalutamide is an investigational combination therapy being evaluated for the treatment of advanced solid tumors, with a focus on hormone receptor-positive, HER2-negative (HR+/HER2−) advanced or metastatic breast cancer. PF-07220060 is a novel, highly selective, next-generation small molecule inhibitor of cyclin-dependent kinase 4 (CDK4), characterized by significant sparing of CDK6, which may result in a distinct safety and efficacy profile compared to dual CDK4/6 inhibitors. Enzalutamide is a nonsteroidal androgen receptor inhibitor that functions by blocking multiple activities along the androgen receptor signaling pathway, mainly used in prostate cancer but under investigation in various settings. The combination is currently in early clinical stages to determine its safety, tolerability, and anti-tumor activity.